使用ACTIONS表型评估的系统性共病负担可预测经尿道前列腺电切术后泌尿科药物停用
该研究评估了ACTIONS健康表型评分(涵盖焦虑、心血管、睾酮、胰岛素/糖尿病、肥胖、神经、睡眠呼吸暂停7个维度)对良性前列腺增生患者经尿道前列腺电切术后症状及药物停用的影响。319例患者中,停用α受体阻滞剂或5α还原酶抑制剂者平均ACTIONS评分显著低于未停用者(3.37±2.14 vs 4.79±2.75,P<.0001),ACTIONS评分<4与药物停用显著相关(P=.0014)。结论认为较低的ACTIONS评分与术后BPH药物停用相关,该评分可能有助于术前咨询。
要点
- 停用α受体阻滞剂或5α还原酶抑制剂者平均ACTIONS评分为3.37±2.14,未停用者为4.79±2.75,P<.0001。
- ACTIONS评分<4与BPH药物停用显著相关(P=.0014)。
- 睾酮(P=.04)、神经(P=.003)和睡眠呼吸暂停(P=.04)维度评分较低与药物停用显著相关。
核心结论
- 较低的ACTIONS评分与TURP术后BPH药物停用相关,提示共病负担较低的患者术后效果更好。
- ACTIONS表型评分易于计算,可能有助于接受TURP的BPH患者的术前咨询。
研究设计与样本
- 研究纳入2004年至2015年因BPH接受TURP的男性患者,共319例,中位年龄74.0岁(四分位距67-78)。
- 采用经验证的ACTIONS表型评估共病,每个维度(焦虑、心血管、睾酮、胰岛素/糖尿病、肥胖、神经、睡眠呼吸暂停)评分为0至2分。
- 评估指标包括BPH药物停用、国际前列腺症状评分变化、残余尿量和患者满意度,显著性水平设为P<.05。
主要发现
- 停用α受体阻滞剂或5α还原酶抑制剂的男性平均ACTIONS评分显著低于未停用者(3.37±2.14 vs 4.79±2.75,P<.0001)。
- ACTIONS评分<4与药物停用显著相关(P=.0014)。
- 睾酮维度评分较低(P=.04)、神经维度评分较低(P=.003)和睡眠呼吸暂停维度评分较低(P=.04)均与药物停用显著相关。
- 总ACTIONS评分与国际前列腺症状评分变化或残余尿量变化无独立关联。
关键数值与推荐
- ACTIONS表型每个维度评分为0至2分。
- 停用α受体阻滞剂或5α还原酶抑制剂者平均ACTIONS评分为3.37±2.14,未停用者为4.79±2.75(P<.0001)。
- ACTIONS评分<4与药物停用显著相关(P=.0014)。
- 睾酮维度评分较低与药物停用显著相关(P=.04)。
- 神经维度评分较低与药物停用显著相关(P=.003)。
临床怎么用
- 作者认为ACTIONS表型评分易于计算,可能有助于接受TURP的BPH患者的术前咨询。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of systemic comorbidities on a validated health phenotype score (ACTIONS: Anxiety, Cardiovascular, Testosterone, Insulin/diabetes, Obesity, Neurologic, Sleep apnea) on outcomes of transurethral resection of prostate (TURP) for benign prostatic hyperplasia (BPH) for symptoms and medication discontinuation. MATERIALS AND METHODS: Comorbidities of men undergoing TURP for BPH from 2004 to 2015 were assessed with the validated ACTIONS phenotype totaling a score from 0 to 2 for each domain (Anxiety, Cardiovascular, Testosterone, Insulin/diabetes, Obesity, Neurologic, Sleep apnea). BPH medication discontinuation, change in International Prostate Symptom Score, postvoid residual, and patient satisfaction were assessed. Descriptive and comparative statistics were calculated with significance set at P <.05. RESULTS: The 319 men had a median age of 74.0 (interquartile range 67-78). Mean ACTIONS score was significantly lower in men who discontinued alpha-blockers or 5-alpha reductase inhibitors compared to those who did not (3.37 ± 2.14vs 4.79 ± 2.75, P <.0001). ACTIONS score <4 was significantly associated with medication discontinuation (P = .0014). Lower scores in Testosterone (P = .04), Neurologic (P = .003), and Sleep apnea (P = .04) domains were significantly associated with medication discontinuation. Total ACTIONS score was not independently associated with changes in International Prostate Symptom Score or postvoid residual. CONCLUSION: Lower ACTIONS score was associated with BPH medication discontinuation after TURP, suggesting men with lower comorbidity burdens do better after the procedure. The ACTIONS phenotype score is easily calculated and may aid the preoperative counseling of men undergoing TURP for BPH.
引用
- Zhang JH, Gill BA, Wilkins L, et al. Systemic Comorbidity Burden Using the ACTIONS Phenotype Predicts Urologic Medication Discontinuation Following Transurethral Resection of the Prostate. Urology. 2019. PMID: 30822484. doi:10.1016/j.urology.2019.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。